Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 10,733 Shares of Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 10,733 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $113,018.49. Following the sale, the chief financial officer now directly owns 105,162 shares in the company, valued at approximately $1,107,355.86. The trade was a 9.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bioventus Trading Up 3.0 %

Bioventus stock opened at $11.00 on Friday. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a market cap of $892.71 million, a PE ratio of -18.03 and a beta of 0.79. The stock has a 50-day moving average of $11.86 and a two-hundred day moving average of $9.77. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Bioventus (NYSE:BVS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same period last year, the firm posted $0.05 EPS. On average, research analysts anticipate that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Large investors have recently made changes to their positions in the stock. Royce & Associates LP purchased a new position in Bioventus in the 3rd quarter worth $8,337,000. Renaissance Technologies LLC raised its stake in shares of Bioventus by 401.5% in the second quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock worth $2,893,000 after purchasing an additional 402,841 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Bioventus during the third quarter worth about $4,515,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Bioventus in the third quarter valued at approximately $3,092,000. Finally, State Street Corp increased its holdings in Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after buying an additional 189,216 shares during the period. 62.94% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Canaccord Genuity Group increased their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Craig Hallum increased their target price on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Finally, JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their target price for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.